Yao W - Search Results

1

Expression of Death Receptor 4 Is Positively Regulated by MEK/ERK/AP-1 Signaling and Suppressed upon MEK Inhibition.

Yao W, Oh YT, Deng J, Yue P, Deng L, Huang H, Zhou W, Sun SY. Yao W, et al. J Biol Chem. 2016 Oct 7;291(41):21694-21702. doi: 10.1074/jbc.M116.738302. Epub 2016 Aug 30. J Biol Chem. 2016. PMID: 27576686 Free PMC article.

2

Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells.

Yao W, Yue P, Zhang G, Owonikoko TK, Khuri FR, Sun SY. Yao W, et al. Cancer Lett. 2015 Aug 1;364(1):70-8. doi: 10.1016/j.canlet.2015.04.028. Epub 2015 Apr 29. Cancer Lett. 2015. PMID: 25937299 Free PMC article.

3

The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5.

Han B, Yao W, Oh YT, Tong JS, Li S, Deng J, Yue P, Khuri FR, Sun SY. Han B, et al. Among authors: yao w. Oncotarget. 2015 Jul 10;6(19):17532-42. doi: 10.18632/oncotarget.3947. Oncotarget. 2015. PMID: 26009898 Free PMC article.

4

The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition.

Yao W, Yue P, Khuri FR, Sun SY. Yao W, et al. Oncotarget. 2015 Oct 27;6(33):34669-79. doi: 10.18632/oncotarget.5785. Oncotarget. 2015. PMID: 26415225 Free PMC article.

5

Correction: Expression of death receptor 4 is positively regulated by MEK/ERK/AP-1 signaling and suppressed upon MEK inhibition.

Yao W, Oh YT, Deng J, Yue P, Deng L, Huang H, Zhou W, Sun SY. Yao W, et al. J Biol Chem. 2020 Jun 26;295(26):8871. doi: 10.1074/jbc.AAC120.014436. J Biol Chem. 2020. PMID: 32591447 Free PMC article. No abstract available.

6

Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.

Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, Kanteti R, Riehm J, Salgia R, Owonikoko TK, Ramalingam SS, Chen M, Sun SY. Shi P, et al. Among authors: yao w. Cancer Lett. 2016 Oct 1;380(2):494-504. doi: 10.1016/j.canlet.2016.07.021. Epub 2016 Jul 19. Cancer Lett. 2016. PMID: 27450722

7

MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers.

Gu J, Yao W, Shi P, Zhang G, Owonikoko TK, Ramalingam SS, Sun SY. Gu J, et al. Among authors: yao w. Cancer. 2020 Aug 15;126(16):3788-3799. doi: 10.1002/cncr.32996. Epub 2020 Jun 4. Cancer. 2020. PMID: 32497272 Free PMC article.

8

Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis.

Zhao W, Yu D, Chen Z, Yao W, Yang J, Ramalingam SS, Sun SY. Zhao W, et al. Among authors: yao w. Cancer Lett. 2021 Oct 28;519:141-149. doi: 10.1016/j.canlet.2021.07.007. Epub 2021 Jul 8. Cancer Lett. 2021. PMID: 34245854

9

Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-X_L dual inhibitor that induces Bax-dependent apoptosis.

Yao W, Bai L, Wang S, Zhai Y, Sun SY. Yao W, et al. Neoplasia. 2022 Jul;29:100798. doi: 10.1016/j.neo.2022.100798. Epub 2022 Apr 21. Neoplasia. 2022. PMID: 35462114 Free PMC article.

10

Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy.

Qian G, Yao W, Zhang S, Bajpai R, Hall WD, Shanmugam M, Lonial S, Sun SY. Qian G, et al. Among authors: yao w. Cancer Lett. 2018 Oct 28;435:44-54. doi: 10.1016/j.canlet.2018.07.033. Epub 2018 Jul 29. Cancer Lett. 2018. PMID: 30059709

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,536 results

Search Page

Filters